Videos

Close Video

HZD.L (0.00%)

52wk Low / High
/
Market Cap
£0.00m
Shares in Issue
96.57m
Earnings Per Share (TTM)
-
Current PE Ratio (TTM)
-
Div / Yield
- / -

Quotes delayed, except where indicated otherwise. Currency in GBp.

Overview

Horizon Discovery Group PLC is a UK life science company that uses gene editing and gene modulation platforms to produce cells, applying them in research and clinical applications that advance human health. The Company’s gene editing and gene modulation platform, are able to alter almost any DNA sequence or RNA transcription, has generated a catalogue of over 1,000,000 cell and reagent products that help researchers recapitulate the genetic and protein anomalies found in diseases like cancer. These models have been adopted by c12,000 organizations to better understand of the predictors and drivers of disease and drug response, and by Horizon in a range of services offered to customers, as well as in the Company’s own research R&D pipeline

Horizon is headquartered in Cambridge, UK, and is listed on the London Stock Exchange’s AIM market under the ticker “HZD”.

www.horizondiscovery.com

Directors

  • Ian Gilham (Chair) – NE Chair of Multiplicom NV, and Biosurfit SA. He is Director of Stowheath Ltd.,and is NE Chair at Epistem Holdings plc, and is on the Board of Vernalis
  • Dr Darrin Disley (CEO) – Raised c$200m business financing from grant, angel, corporate, vc & public market. Closed c$350m of product, service & licensing deals.
  • Richard Vellacott (CFO) – 15yrs as a chartered accountant.
  • NED’s – Mrs Susan Earle, Dr Susan Galbraith, Grahame Cook, Vishal Gulati, Jonathan Milner

Financials

P&L2014
£~000
2015
£~000
Revenue11,90520,060
Operating Profit / (Loss)(5,350)(10,290)
Profit / (Loss) before tax(6,073)(10,540)
BALANCE SHEET2014
£~000
2015
£~000
Total assets65,68088,870
Cash & cash equivalents18,21525,067
Total liabilities7,1669,014
Net assets58,51479,856

Peer Group

  • Abcam (AIM: ABC): Life Science research
  • Bachem (SIX: BANB): Manufactures ingredients for pharmaceuticals, generic drugs & research supplies
  • Epistem Holdings (LSE: EPH): Stem cell treatment for oncology & gastrointestinal diseases
  • Sigma Aldrich (NASDAQ: SIAL): Develops broad rang of chemicals, biochecmicals & equipment
  • Qiagen (NASDAQ: QGEN): Provides samples & assy technologies

Major Shareholders

Directors

  • Dr J Milner – 10.31%
  • Dr D Disley – 0.73%
  • Mr Grahame Cook – 0.04%
  • Mrs Susane Searle – 0.05%
  • Dr Ian Gilham – 0.03%

Other

  • Invesco – 12.11%
  • Telegraph Hill Partners – 11.18%
  • Henderson Global Investors – 10%
  • Legal & General – 7.23%
  • Aviva – 6.31%
  • Baillie Gifford – 5.15%
  • DFJ Esprit – 5.04%

Macro Indicators

“The new science of personalised medicine” (PWC report 2011).

Currently, the total US market for personalised medicine and healthcare (wide, by definition) is estimated at £149bn and is projected to surpass £288bn by 2015

The core diagnostic and therapeutic segment (pharmaceuticals, medical device and diagnostic companies) is estimated at £15bn, with an estimated annual growth rate of c.10%, to reach £27bn by 2015.

30% of all pharma companies now require research & development compounds to have a patient-relevant biomarker

Media coverage

Investor’s Chronicle (17 Apr 2015)
“Final Results out this week revealed that the Co had outperformed expectations, with full year revenues rising to £11.9m, 8% ahead of consensus estimates. BUY”

Mail on Sunday (23 Mar 2015)
“Discover the life science firm that will broaden your horizons.”

Shares (Dec 2014)
“15 for 2015: Horizon Discovery”

Broker Coverage

Panmure Gordon (House Broker)
“Horizon offers investors a rare opportunity to gain exposure to an enabling healthcare company operating a unique and enabling technology platform within its chosen markets.”

Submit your details to be kept up to date with announcements regarding Horizon Discovery Group Plc

We have a strict data protection policy and will not share your details with external parties.